IMPL Impel Pharmaceuticals Inc (PK)

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
WASHINGTON, D.C. 20549

FORM 8-K

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

Date of Report (Date of earliest event reported) April 9, 2009

 Nevada 333-140236
 -------- ---------- ------------------
(State or other jurisdiction (Commission File Number) IRS Employer
of incorporation) Identification No.)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

[ ] Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

[ ] Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

[ ] Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))

[ ] Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

ITEM 5.03 AMENDMENTS TO ARTICLES OF INCORPORATION OR BYLAWS; CHANGE IN FISCAL YEAR.

On April 9, 2009 the Company merged its wholly-owned Nevada subsidiary, Consorteum Holdings, Inc., with and into itself and in connection with such merger changed its name from Implex Corporation to that of the subsidiary, Consorteum Holdings, Inc. Except for the change in the Company's name, there were no other changes to the Articles of Incorporation.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

IMPLEX CORPORATION

 By: /s/ Richard C. Fox, Pres./CEO
 ------------------

Dated: April 14, 2009

Impel Pharmaceuticals (PK) (USOTC:IMPL)
Historical Stock Chart
From Jun 2024 to Jul 2024

Impel Pharmaceuticals (PK) (USOTC:IMPL)
Historical Stock Chart
From Jul 2023 to Jul 2024